Showing results (41-50 of 182) with videos related to
Sort By:
Pageof 19
Current Hematologic Malignancy Reports|April 22, 2016
Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis FungoidesMeenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, et al.Pathology|November 14, 2014
Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factorsMelissa Pulitzer, Patricia L Myskowski, Steven M Horwitz, et al.The Journal of Dermatological Treatment|September 25, 2018
Treatment of Rosai-Dorfman disease with oral bexarotene: a case seriesShamir Geller, Klaus Busam, Paul A Hamlin, et al.Blood Advances|January 24, 2019
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphomaNeha Mehta-Shah, Kimiteru Ito, Kurt Bantilan, et al.Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.JCO Oncology Practice|July 30, 2020
Survivorship Care Plans: Reaching a Benchmark and Striving to Achieve IntentRobert Stuver, Jennifer Faig, Matthew Cadorette, et al.Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS|February 4, 2020
Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implantsPeter G Cordeiro, Paola Ghione, Andy Ni, et al.Journal of the American Academy of Dermatology|September 10, 2019
Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer centerShamir Geller, Emily Lebowitz, Melissa P Pulitzer, et al.Journal of the American Academy of Dermatology|September 27, 2008
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximabAnjali V Morales, Ranjana Advani, Steven M Horwitz, et al.Leukemia & Lymphoma|July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysisEfrat Luttwak, Edith Tama Robin, Esther Drill, et al.Pageof 19